Alan T Remaley
Lipoprotein Metabolism Section
National Institutes of Health, USA
Alan T. Remaley, M.D., Ph.D is a medical officer in the Public Health Service at the National Institutes of Health. Dr. Remaley received his B.S. in Biochemistry and Chemistry from the University of Pittsburgh in 1981. He received in 1987 a M.D. and Ph.D. (Biochemistry) degree from the University of Pittsburgh. He completed in 1990 a residency in Clinical Pathology at the University of Pennsylvania and became board certified in Clinical Pathology in 1992. He joined the National Institutes of Health in 1990, as a medical staff fellow, and did a postdoctoral fellowship on lipoprotein metabolism at the Molecular Disease Branch of the National Heart, Lung, and Blood Institute. He became in 1995 a senior staff member of the Department of Laboratory Medicine at the National Institutes of Health, where he directs the Immunoassay and HPLC/Mass Spectrometry laboratories. As of 2005, he became the section chief of the Lipoprotein Metabolism Laboratory at NHLBI. His current research is focused on the mechanism of action of the ABCA1 transporter and its role in HDL metabolism. In addition, he is involved in developing new diagnostic immunoassays and lipoprotein assays. He is the author of over 150 publications, mostly in the fields of lipoprotein metabolism and clinical pathology, and has four patents. He is a member of the editorial board for Clinical Chemistry, Open Atherosclerosis, and Journal of Pediatric Clinical Biochemistry. He is a current member of the FDA Advisory Board for Clinical Chemistry/Clinical Toxicology Devices and a member of the CAP Proficiency Test Committee for Special Chemistry. He is a past chair of the Capital Section of the American Association of Clinical Chemistry and the Lipoprotein and Vascular Disease Division of the American Association of Clinical Chemistry.
Mechanism of action of the ABCA1 transporter and its role in HDL metabolism